Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Celo upgrades the OP-Succinct Lite implementation on its mainnet to SP1 Hypercube zkVM

Celo upgrades the OP-Succinct Lite implementation on its mainnet to SP1 Hypercube zkVM

ForesightNewsForesightNews2026/05/27 07:02
Show original

Foresight News reports that Celo has announced an upgrade to the OP-Succinct Lite implementation on its mainnet, adopting the next-generation SP1 Hypercube zkVM launched by Succinct Labs. The upgrade introduces a completely new proof architecture, reducing proof latency and enhancing overall efficiency, further strengthening Celo's zk fault proof infrastructure. Celo stated that this collaboration aims to improve the scalability and performance of its network.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

UBS is bullish on CoreWeave (CRWV.US): Initiates "Buy" rating, betting on the return of AI trading rotation.

UBS has initiated coverage of the emerging cloud service provider CoreWeave (CRWV.US) with a "Buy" rating and set a target price of $120.

智通财经2026/09/24 07:01

Sixth increase in six years! Disney(DIS.US) raises the monthly fee for Disney+ ad-free version by 13% to $21.49.

Walt Disney Company (DIS.US) is raising subscription prices for several of its streaming services in the U.S. market, marking the sixth price increase in six years, as the company aims to boost the profitability of its streaming business, which is crucial for Disney's future.

智通财经2026/09/24 06:51

Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth

On September 24, according to the CDE website, Johnson & Johnson’s (JNJ.US) talquetamab (Chinese brand name: Tuolike) is proposed to be included in priority review.

智通财经2026/09/24 06:51
Johnson & Johnson (JNJ.US) Tarlatamab to be included in China's priority review, aimed at inhibiting tumor formation and growth